The Comparative Brain Tumor Consortium is collaborating with National Center for Advanced Translational Sciences to complete a high-throughput drug cell line screen. Three canine astrocytic glioma cell lines and two pediatric glioblastoma cell lines are included in the screen, which includes libraries of thousands of FDA-approved and investigational agents. Agents developed for oncology indications as well as non-oncology drugs were screened to support drug-repurposing hypotheses. Results will be made publically available.
This effort is being led by Dr. Matthew Hall.